Cargando…
Persistent drop in confidence following US recommended pause of Ad26.COV2.S vaccine administration
The Janssen COVID-19 vaccine came to market in February 2021 as the first non-mRNA and first single-dose formula approved for use in the US. In April 2021, a temporary pause was recommended for the vaccine after the discovery of rare but serious post-vaccination side-effects. We fielded a large-scal...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Author(s). Published by Elsevier Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692206/ https://www.ncbi.nlm.nih.gov/pubmed/36443155 http://dx.doi.org/10.1016/j.vaccine.2022.11.035 |